A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours-Reference-Cited by-同舟云学术

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours

Published:2014-03 Issue:5 Volume:50 Page:867-875
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tolcher Anthony,Goldman Jonathan,Patnaik Amita,Papadopoulos Kyriakos P.,Westwood Paul,Kelly Claudia S.,Bumgardner William,Sams Lillian^ORCID,Geeganage Sandaruwan,Wang Tao,Capen Andrew R.,Huang Jianping,Joseph Sajan,Miller Joel,Benhadji Karim A.,Brail Les H.,Rosen Lee S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Exploiting the PI3K/AKT pathway for cancer drug discovery;Hennessy;Nat Rev Drug Discov,2005

2. AKT and cancer – is it all mTOR?;Rosen;Cancer Cell,2006

3. Ras, PI(3)K and mTOR signalling controls tumour cell growth;Shaw;Nature,2006

4. A complex interplay between Akt, TSC2 and the two mTOR complexes;Huang;Biochem Soc Trans,2009

5. TOR controls translation initiation and early G1 progression in yeast;Barbet;Mol Biol Cell,1996

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome;Nature Aging;2024-08-29

2. Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma;Cancer Research Communications;2024-08-01

3. Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia;Blood Advances;2024-07-24

4. Driving proteomic imbalance to combat Neurofibromatosis type I (NF1)-associated malignancy;2024-05-27

5. SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma;Science Translational Medicine;2024-05-15